GAA and coronary artery disorder: The Acarbose Cardiovascular Evaluation (ACE) trial assessed the effects of acarbose, an alpha‐glucosidase inhibitor, in 6522 patients with coronary heart disease (CHD) and IGT from 176 hospital outpatient clinics in China.